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Background: Vascular smooth muscle cells (SMC) are central to arterial structure and function yet their
involvement in the progression of abdominal aortic aneurysm (AAA) disease is not well studied. The progressive
and silent nature of AAA in man essentially restricts research to the use of “end-stage” tissue recovered during
surgical repair. This study aimed to generate an ex vivo model of AAA using protease-treated porcine carotid
arteries maintained in a novel bioreactor, and to compare the structural and functional changes in SMC cultured
from the recovered vessels with those from human tissue acquired at elective surgical repair.
Methods: Freshly isolated porcine arteries were pretreated with collagenase and/or elastase before culturing under
flow in a bioreactor for 12 days. Human end-stage aneurysmal tissue and saphenous veins from age-matched
controls were collected from patients undergoing surgery. SMC were cultured and characterised
(immunocytochemistry, measurement of spread cell area) and assessed functionally at the level of proliferation
(cell-counting) and matrix-metalloproteinase (MMP) secretion (gelatin zymography). Cellular senescence was
investigated using β-galactosidase staining and apoptosis was quantified using a fluorescence-based caspase 3 assay.
Results: Co-expression of alpha-smooth muscle actin and smooth muscle myosin heavy chain confirmed all cell
populations as SMC. Porcine SMC harvested and cultivated after collagenase/elastase pretreatment displayed a prominent
“rhomboid” morphology, increased spread area (32%, P < 0.01), impaired proliferation (47% reduction, P < 0.05), increased
senescence (52%, P < 0.001), susceptibility to apoptosis and reduced MMP-2 secretion (60% decrease, P < 0.01) compared
with SMC from vehicle, collagenase or elastase pre-treated vessels. Notably, these changes were comparable to
those observed in human AAA SMC which were 2.4-fold larger than non-aneurysmal SMC (P < 0.001) and
exhibited reduced proliferation (39% reduction, P < 0.001), greater apoptosis (4-fold increase, P < 0.001), and
increased senescence (61%, P < 0.05).
Conclusions: Combined collagenase/elastase exposure of porcine artery maintained in a bioreactor under flow
conditions induced a SMC phenotype characteristic of those cultured from end-stage AAA specimens. This
model has potential and versatility to examine temporal changes in SMC biology and to identify the molecular
mechanisms leading to early aberrancies in SMC function. In the longer term this may inform new targets to
maintain aortic SMC content and drive cells to a “reparative” phenotype at early stages of the disease.
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Abdominal aortic aneurysm (AAA) rupture carries an ~80%
mortality risk and is responsible for 6000 deaths annu-
ally in the UK, accounting for 2% of all deaths in men
aged >65 years (www.aaa.screening.nhs.uk). Once established,
AAA progressively evolves towards rupture which is cor-
related with maximal aneurysm diameter. Intervention by
either open surgery or endovascular repair is offered once
the annual risk of rupture outweighs the mortality risk as-
sociated with intervention [1]. Clinical risk factors for
AAA include male gender, age, hypertension, smoking
and a family history of aneurysm disease.
The pathology of AAA encompasses infiltration by in-
flammatory cells (macrophages and lymphocytes), apop-
tosis of smooth muscle cells (SMC) within the aortic
wall, and degradation of the extracellular matrix (ECM)
which severely compromises the structural integrity of
the vessel rendering it susceptible to rupture [2]. The in-
flammatory characteristics of AAA have been a major
research focus for many years (reviewed in [3]), yet com-
paratively fewer investigations have considered the role of
SMC. Given the inherent plasticity of SMC to remodel
vascular walls through acquisition of a dedifferentiated,
secretory phenotype [4], this is perhaps surprising.
SMC are the principal resident cells of the aortic wall and
are essential in maintaining its structure through controlled
proliferation and by secretion and turnover of ECM. Whilst
SMC secrete the “building blocks” of ECM (collagens, elas-
tin etc.), they also secrete matrix metalloproteinases (MMPs)
that are involved in ECM breakdown [5]. The most exten-
sively characterised with respect to AAA are the gelatinases
MMP-2 and MMP-9, both of which are expressed at ele-
vated levels in human and animal AAA tissue specimens
[6,7]. Importantly, MMP-2 or MMP-9-deficient mice fail to
develop experimental aneurysms [8]. Thus, SMC are capable
of maintaining a dynamic ECM that can respond and adapt
to the physiological environment [4]. However, during AAA
development, inflammatory infiltrates contribute additional
proteolytic activity within the ECM and induce SMC apop-
tosis [5,9], severely compromising vessel tone and structure.
SMC within the aortic media are unique in their potential
to induce repair in the damaged vessel and this makes them
an appealing target for further detailed study.
A major obstacle to AAA research is that human tissue
is not available in the early, silent phase of the disease and
specimens acquired at the time of surgical repair are likely
to have endured cellular and molecular changes over an
extended period. A number of studies have elucidated evi-
dence that supports alterations in oxidative stress [10],
proliferation [11,12] and MMP-2 activity [11,13] in human
AAA-SMC compared to non-aneurysmal SMC. However,
by the very nature of the “end-stage” tissue it is not pos-
sible to define aberrations in SMC biology that are likely
to occur early in disease progression. Murine or rodentmodels have been generated to facilitate this type of re-
search and include methods that utilise elastase or angio-
tensin II infusion, or application of calcium chloride to the
exposed adventitia of the aorta (reviewed in [14]). These
generally result in aneurysm formation within 2-4 weeks.
A decellularised guinea pig to rat xenograft model of
aneurysm development has also been described [15,16];
however rodent vessel physiology does not mimic human
vessels as closely as those from larger animals. An in vivo
porcine model of infrarenal aneurysm has been investi-
gated [17], and porcine carotid arteries have previously
been used ex vivo in a bioreactor to study the effect of
stent implantation [18]. More recently, an in vitro bioreac-
tor model of aneurysm has been described [19] in which
PTFE grafts were firstly dilated with a balloon catheter
and subsequently seeded with human SMC which over
14 days formed a full “neointima” over the dilated vessel.
The aim of this study was to generate a novel ex vivo
model of AAA to study the fate, phenotype and function
of the SMC specifically. This was undertaken by brief
protease exposure of porcine vessels followed by culture
under flow conditions in a bioreactor for 12 days. SMC
subsequently isolated and cultured from these vessels
were then compared with SMC cultured from end-stage
human AAA tissue.
Methods
Establishing porcine vessels in the bioreactor
Left and right porcine carotid arteries (PCA) were harvested
aseptically from four-month old 65 kg pigs sedated with
Stresnil, anaesthetised with Hypnovel and terminated via
Pentoject injection. All animal procedures were conducted
according to UK Home Office Regulations. Vessels were
cleaned of adventitia and superfluous fat, and thin “rings” of
vessel (~2-3 mm length) were cut, immediately fixed in for-
malin and processed for histology. A further tissue fragment
was used to prepare SMC from the freshly isolated artery,
whilst the remaining vessels were used to prepare two
equivalent lengths of artery (each approx 6 cm) which were
treated as follows. Ultrapure LMP agarose (Invitrogen)
was reconstituted in Hanks balanced salt solution (HBSS,
Invitrogen) to form a gel (1% w/v) and this vehicle was ap-
plied to control arteries. Enzyme treatments were incorpo-
rated into vehicle gel as required (3 mg/ml Type 1A
collagenase, 390 U/mg (Sigma-Aldrich); 1.5 mg/ml por-
cine pancreatic elastase, 50 U/mg (MP Biomedical) or in
combination) to the mid-section (~ 2 cm) of the adventi-
tial surface of the vessel using a small brush. Consistency
of application was achieved by immobilising the vessels in
a sterile dish such that equal volumes (1 ml) of treatment
were applied to and retained around this mid-portion dur-
ing exposure. After a 3 h incubation period at 37°C in a
humidified incubator, the vessels were rinsed thoroughly
in HBSS and mounted in the bioreactor. In brief, the
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and tied securely with sutures. This was placed inside a
stainless steel supporting chamber that was sealed by fix-
ing a custom-made glass plate onto the front long aspect
(Figure 1A). Flow was generated using a peristaltic pump
which drew culture medium from a primary reservoir be-
fore pumping it through a second reservoir in order to
eliminate pulsations from the peristaltic pump. Culture
medium was delivered via the inlet cannula, flowed
through the arterial lumen and exited through the outlet
cannula into the chamber. By this means, the exterior of
the artery was also continually perfused, with the medium
flowing through an exit port and back to the reservoir (see
Figure 1B). Each chamber was subjected to identical con-
ditions in separate, steady flow loops of ~120 ml/min
using culture medium containing 30% foetal calf serum
(FCS) [20] and gassed with 5% CO2 in air at 37°C for
12 days.
After the culture interval, vessels were carefully recov-
ered, a section was fixed and prepared for histology and
the remaining portions were allocated to SMC culture,
ultimately yielding cells derived from vehicle (VEH), col-
lagenase (C), elastase (E) or combination (CCE) treat-
ment groups.
Histological examination of intact vessels
Formalin-fixed vessels were processed, paraffin-embedded
and sectioned to 5 μm. Sections were stained with anti-
alpha smooth muscle actin (α-SMA) and Millers elastin as
previously described [21]. Images were captured using aA.
B.
Sutures
Porcine carotid artery 
(PCA)
Flow loops from peristaltic 
pump (out of picture)
Figure 1 Bioreactor. (A) Segments of PCA were secured between stainles
plate onto the supporting chamber. (B) Culture medium was circulated fro
perfuse the interior of the vessel, before leaving through the outflow cann
to the reservoir by flowing through the exit port. Vessels were perfused at
SMC explant culture.Zeiss AxioVision Imaging System (AxioCam HRc camera
on an AxioImager Z.1 microscope).
SMC isolation and culture
AAA tissue (anterior abdominal aortic wall) was obtained
from patients undergoing open repair of the infra-renal
abdominal aortic aneurysm, and SV fragments obtained
from age-and sex-matched patients undergoing coronary
artery bypass grafting at Leeds General Infirmary, UK.
Local ethical committee permission and informed, written
patient consent was obtained, and the study conformed to
the principles outlined in the Declaration of Helsinki.
Human aortic SMC (1 donor) were purchased from a
commercial source. Porcine vessels were used either
directly after harvesting (fresh) or upon removal from
the bioreactor. From all human and porcine freshly
isolated vessels, SMC cultures were established by an
explant technique we described previously [22]. Cells were
maintained in Dulbecco’s Modified Eagle Medium (DMEM)
supplemented with 10% FCS, 1% L-Glutamine and 1% peni-
cillin / streptomycin fungizone (full growth medium; FGM)
at 37°C in 5% CO2 in air. SMC were serially passaged using
trypsin/EDTA as necessary and used for experiments be-
tween passages 2-5.
SMC morphometric analysis
SMC were seeded at a density of 2×105 cells per 75 cm2
flask in FGM and cultured for 96 h. Using light micros-
copy (× 100 magnification) at least 10 fields of view were






s steel cannulae. The chamber was assembled by sealing a glass front
m a reservoir via a peristaltic pump through the inlet cannula to
ula and perfusing the exterior of the vessel. Media was then returned
constant flow rate for 12 days prior to harvesting for histology and
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was calculated using Image J software (http://imagej.nih.
gov/ij/).
Immunocytochemistry
SMC were seeded at a density of 2×103 in chamber slides,
cultured for 4 days in FGM then fixed in 4% paraformal-
dehyde. Immunostaining for smooth muscle myosin heavy
chain (SM-MHC) and α-SMA was performed as we previ-
ously described [23]. SMC were visualised using a Zeiss
LSM 510 confocal microscope (× 400 magnification).
Proliferation assays
Proliferation assays were performed as described previ-
ously [23]. Briefly, cells were seeded at 1x104 cells per
well in 24-well plates, allowed to establish overnight
(~18 h) and quiesced in serum-free medium (SFM) for
72 h before performing cell counts in triplicate using
trypan blue and a haemocytometer. These counts were
designated “day 0”. Cells were then replaced into FGM
and further triplicate counts taken on days 2, 4 and 7,
with medium being replaced on days 2 and 4. Prolifera-
tion curves were plotted and area under the curve
(AUC) analysis was performed using GraphPad Prism
software (www.graphpad.com).
Apoptosis assay
SMC were plated in 96-well plates at a density of 3×103
cells per well in FGM and established overnight. Cells
were treated with 5 μmol/L NucView™ 488 caspase-3
substrate (Biotium) according to manufacturer’s instructions
in the absence and presence of 50 nmol/L staurosporine
(Sigma-Aldrich). Plates were incubated and imaged using an
IncuCyte FLR time-lapse fluorescence microscope (Essen
Bioscience) for up to 24 h in phase contrast and fluores-
cence mode using a ×10 objective, after which all cells were
stained using 1 μmol/L Vybrant DyeCycle Green® (Molecu-
lar Probes, Invitrogen) and quantified using an inbuilt algo-
rithm to calculate an apoptosis index.
Senescence-associated β-galactosidase assay
SMC were seeded at 7.5×104 cells per well in 6 well plates
and cultured for 48 h in FGM. Cell senescence was quan-
tified using a commercial assay of β-galactosidase (Cell
Signaling Technology), according to manufacturer’s in-
structions. This assay histochemically detects expression
of senescence-associated β-galactosidase at pH 6, resulting
in a blue precipitate. Ten low power (× 40 mag.) micro-
scopic fields were imaged from each well and a senescence
score was calculated.
Gelatin zymography
SMC were seeded at a density 2×105 cells per 25 cm2
flask in FGM, established for 24 h, quiesced in SFM for72 h, and then treated with medium containing 0.4% FCS or
supplemented with phorbol ester 12-O-tetradecanoylphorbol-
13-acetate (TPA, 100 nmol/L, Sigma-Aldrich) for a further
48 h. Conditioned medium (CM) was then collected,
centrifuged to remove cell debris, snap frozen in liquid nitro-
gen and stored at −80°C until required. Gelatin zymography
of CM was performed as described previously [22].
Statistical analysis
All data are expressed as mean ± SEM with n representing
the number of experiments on cells from different pa-
tients/animals. Differences between treatment groups
were analysed using paired (for porcine) or non-paired
(for human) ratio t-tests or repeated measures one-way
ANOVA with Newman-Keuls post-hoc tests as appro-
priate. P < 0.05 was considered statistically significant.
Results
Application of collagenase and elastase induces
morphological changes in the PCA
Freshly isolated PCA was compared with VEH treated
vessel recovered after 12 days in the bioreactor. Gross
appearance of the vessels was comparable and all layers
were intact (Figure 2A,B). Conversely, all enzyme-treated
vessels displayed variable degrees of degenerative changes
in the wall (Figure 2C-F). Histological comparison of PCA
pre-treated with VEH (Figure 2C) versus collagenase
revealed a loss of smooth muscle integrity (Figure 2D).
Vessels treated with elastase alone (Figure 2E) or in
combination with collagenase (Figure 2F) also demon-
strated a clear loss of elastin fibres.
Smooth muscle cell phenotype
(i) Porcine carotid arteries
Medial wall cells isolated from both fresh and bioreactor
vessels explanted readily in culture, indicative of their
viability. Cells propagated from VEH control vessels
were indistinguishable from those of fresh vessels and
exhibited a characteristic “spindle” appearance of SMC
(Figure 3A,B). Despite the observed disruption in whole
vessel wall structure, cells cultured from either C-or E-
treated arteries were morphologically comparable to
VEH (Figure 3C,D). In contrast, those isolated from
CCE-treated PCA exhibited a prevalence of flattened,
rhomboid cells (Figure 3E). In all cases, cells stained
positively for SM-MHC and α-SMA confirming their
identity as vascular SMC (Figure 3F).
Quantification of the spread cell areas for each group
corresponded with morphological appearances. Whilst cel-
lular areas for fresh, VEH, C and E did not differ, the mean
spread area of CCE-SMC was ~ 40% greater than that of
VEH-SMC (3720.4 ± 223.2 versus 2707.9 ± 208.5 μm2,
P < 0.05, Figure 3G).
Freshly isolated 12 day bioreactor - VEHA. B.














Figure 2 Histology of PCA. Tissue was fixed at initial harvest (freshly isolated), and after 12 days culture in the bioreactor following pre-
treatment with vehicle control (agarose gel, VEH), collagenase, elastase, or both in combination (CCE). Purple indicates elastin fibres; brown
indicates α-SMA-positive regions. L = lumen, M =media, A = adventitia. Low power (× 50 magnification) images of (A) freshly isolated PCA and
(B) VEH, scale bars = 200 μm. Higher power magnification (× 100) of PCA pre-treated with (C) VEH, (D) collagenase, (E) elastase and (F) CCE, scale
bars = 200 μm. Arrowheads in (E) and (F) indicate sparse areas of preserved, thinned elastin.
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Cells propagated from AAA specimens of 12 different
patients were confirmed as SMC by co-expression of
α-SMA and SM-MHC (Figure 4A). Morphologically,
whilst aortic-SMC and SV-SMC displayed a predomin-
ant spindle appearance, AAA-SMC exhibited clear het-
erogeneity with a predominance of rhomboid cells
(Figure 4B-D). The mean cell area of AAA-SMC was
10,537.0 ± 936.6 μm2, ~ 2.4-fold larger than SV-SMC
(4468.3 ± 335.4 μm2, Figure 4E).SMC proliferation
Porcine SMC proliferation assays were performed over a
7-day interval, over which VEH- SMC and freshly isolated
SMC exhibited identical profiles (Figure 5A). Similarly,
SMC proliferation from bioreactor vessels with C or E
pre-treatment was virtually identical to VEH (Figure 5B,
C). However, CCE-SMC showed a significant reduction
of ~60% versus VEH (P < 0.001, n = 3; Figure 5D).
AAA-SMC proliferation was compared with non-aneurysmal
SV-SMC in a side-by-side manner. Proliferation of AAA-SMC over 7 days was significantly less than that of SV-
SMC (Figure 5E), with ~40% reduction in cell number
over the period (P < 0.001, n = 12).SMC apoptosis
Apoptosis assays were performed basally and in response
to an apoptotic stimulus (staurosporine). All porcine SMC
displayed equivalent levels of basal apoptosis that were
significantly increased following staurosporine treatment
(5-7 fold increase, n = 3, P < 0.05, Figure 6A,B). Whilst
CCE-SMC appeared more susceptible to the apoptosis-
inducing effect of staurosporine, this increase was not sta-
tistically significant (Figure 6A,B).
In human cells, there was a strong trend towards in-
creased basal apoptosis in AAA-SMC compared with
SV-SMC (6.6 A.U. vs. 0.4 A.U.) but not statistically sig-
nificant; there was considerable variability between cell
populations (n = 4, Figure 6C,D). However, following a
24 h exposure to staurosporine there was a marked in-
crease in apoptotic cells in the AAA-compared to SV-SMC
(27.8 A.U. vs. 6.6 A.U.). Staurosporine-induced apoptosis








































Figure 3 PCA SMC morphology. Cells were explanted from both freshly isolated PCA and bioreactor vessels and maintained in cell culture in
full growth medium. Representative phase contrast images of cells explanted from (A) freshly isolated tissue (B), VEH, (C) collagenase, (D) elastase
and (E) CCE-pre-treated vessels, scale bar = 100 μm. (F) Immunocytochemical staining for α-SMA (green) and SM-MHC (red) and co-localisation
(orange). Magnification × 400, scale bar = 100 μm. (G) Mean cell areas of 100 individual cells per condition were quantified using Image J and
expressed relative to the matched freshly isolated vessel. All n = 3, ns = non significant, **P < 0.01.
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stimulation (n = 4, P < 0.001, Figure 6C,D).
SMC senescence
Cellular senescence was evaluated by measuring expres-
sion of β-galactosidase. The incidence of senescent cells
in VEH-SMC was higher than in freshly isolated popula-
tions (1.79 A.U vs. 1.01 A.U. respectively). However,
the extent of senescence in the CCE-SMC was further
elevated to 2.72 A.U. (n = 3, P < 0.001 CCE vs. VEH,
Figure 7A,B).
Human SV-SMC exhibited a basal level of senescence
(2.26 A.U.), and this was significantly higher in AAA-
SMC (3.62 A.U., n = 4, P < 0.05, Figure 7C,D).
Matrix metalloproteinase (MMP) secretion
All freshly isolated SMC secreted MMP-2 constitu-
tively, regardless of source. In porcine cells, basal se-
cretion of MMP-2 was similar in fresh and VEH cells
but was significantly attenuated in CCE-SMC (P < 0.001,
n = 3, Figure 8A,B). In all 3 populations, TPA stimulation
resulted in ~ 2-fold increase in MMP-2 secretion (fresh
P < 0.01; VEH P < 0.05; CCE P < 0.01 versus unstimu-
lated cells) although the absolute levels secreted from
the CCE cells were lower than VEH (P < 0.001, n = 3,Figure 8A,B). Consistent with porcine cells, human SMC
secreted MMP-2 basally and this was further increased by
TPA stimulation in both SV (2-fold, P < 0.05) and AAA
(1.5-fold, P < 0.001; Figure 8C,D).
MMP-9 secretion was not detected under any condi-
tion in porcine or human SMC, either basally or with
TPA stimulation.
Discussion
This study has revealed a number of key findings. Firstly
we maintained viable porcine carotid arteries under flow
conditions in a bioreactor model for 12 days. Histo-
logical examination revealed that vessel wall architecture
in control (VEH) vessels was identical to that of freshly
isolated PCA, but protease-pre-treatments either indi-
vidually or combined, led to visible disruption of the ar-
terial wall. Within the time frame studied and under
these conditions we did not however, observe an unam-
biguous dilatation of the vessel although we speculate
that the thinning we observed preceded overt dilation
which may well become apparent at a later time point.
Secondly, viable cells were cultured from all vessels and
confirmed as SMC through co-expression of α-SMA and
SM-MHC. All porcine SMC exhibited characteristic














































Figure 4 Human SMC morphology. Cells were explanted from human aneurysmal wall tissue (AAA), or human saphenous vein (SV) and
maintained in culture in full growth medium. (A) Immunocytochemical staining of α-SMA (green) and SM-MHC (red) and co-localisation in
human AAA SMC. Magnification ×400, scale bar = 100 μm. (B) Representative phase contrast images of aortic SMC, (C) SV-SMC and (D) human
AAA-SMC, scale bar = 100 μm. (E) The mean cell areas of 100 individual cells per patient were quantified using Image J. All n = 12, ***P < 0.001.
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http://www.translational-medicine.com/content/11/1/208from the combined protease treated vessels that were
more rhomboid, a trait common to dedifferentiated,
often pathological SMC [24]. The aberrancies in PCA-
SMC morphology evident after treatment with CCE
were recapitulated in SMC from end-stage human AAA
tissue. In agreement with a previous report, AAA-SMC
were morphologically distinct (large and rhomboid) from
SV-SMC (smaller, spindle) [12] and also from the aortic
SMC (spindle) obtained from a commercial source.SMC phenotypic switching underlies their unique abil-
ity to elicit compensatory responses to vascular injury.
Indeed, increased SMC proliferation is a prominent fea-
ture of occlusive vascular diseases [25]. Conversely, it is
well established that SMC depletion is a hallmark of
AAA [26,27], which might suggest functional inability of
the SMC to remodel the degenerating aortic wall. In
this study we revealed that AAA-SMC consistently prolifer-
ated more slowly than non-aneurysmal SV-SMC cultured
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Figure 5 SMC proliferation. Cell number was monitored over a 7- day period to generate growth curves in full growth media in the following
SMC groups: (A) Freshly isolated and VEH (n = 3), (B) VEH and collagenase (n = 3), (C) VEH and elastase (n = 3), (D) VEH and CCE (n = 3), and (E)
human SV and AAA-SMC (n = 12). *P < 0.05, **P < 0.01, ***P < 0.001.
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ative capacity of SMC was reduced to a similar degree in
porcine CCE-SMC compared with paired VEH cells. Re-
ports relating to proliferative capacity of AAA-SMC com-
pared to non-aneurysmal SMC are at variance; claims of
both increased [11,28] and decreased proliferation [12]
have been documented. In the latter, AAA-SMC consist-
ently proliferated by up to 70% less than inferior mesenteric
artery SMC [12], comparator cells that were cultured from
the same patients. In the current study we examined SMC
from AAA and SV sources from a total of 24 different pa-
tients. Given our expertise and familiarity with inherent
variability between individual patients [23,29,30] and our
documented evidence supporting the intrinsic heterogen-
eity of SMC populations [31], this is an important aspect of
the current study. Whilst SMC derived from age-matched
non-aneurysmal abdominal aorta may be a superior com-
parator, in the current study this was not a feasible option
and thus a limitation.
Loss of aortic SMC through apoptosis is a prominent fea-
ture of AAA disease [5,27]. The similarity in basal apoptosis
we observed between aneurysmal and non-aneurysmal
SMC concurs with a previous report where no differences
were observed between AAA and matched inferior mesen-
teric artery SMC cultured under standard conditions [12].However, we noted significantly augmented apoptosis in
AAA-SMC upon exposure to staurosporine. It is conceiv-
able that in AAA disease, SMC apoptosis in vivo may be at-
tributable to a heightened sensitivity to apoptotic stimuli in
a significant proinflammatory environment, rather than a
difference in basal apoptosis levels.
Accelerated vascular aging, cell senescence and syn-
thetic SMC phenotypes have been documented in AAA
patients or those with risk factors for AAA [11,12,32,33].
Another common feature of aged cells is that of telo-
mere shortening and this has been demonstrated in both
AAA-SMC [10] and leucocytes of patients with AAA
[34]. Rhomboid SMC are more commonly reported in
pathological states [4] and there is speculation that aging
causes a general switch towards a synthetic phenotype in
vascular SMC [35]. Aging has been demonstrated to
alter SMC proliferation in a variety of ways depending
on source and model, and also to modulate the prolifer-
ative response to growth factors or cytokines [35]. In
keeping with this concept, we also noted differential sen-
escence between PCA vehicle-treated and CCE-SMC,
and likewise between human SV and AAA-SMC. It is
reasonable to suggest that the SMC phenotypes we iden-
tify in both the human AAA and porcine CCE are indi-
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Figure 6 SMC apoptosis. Cells were cultured in FGM ±50 nmol/L staurosporine for 24 h. (A) Representative images of PCA-SMC (green fluorescence
indicates apoptotic cells). Scale bar = 300 μm. (B) Quantification of apoptosis index in PCA-SMC (n = 3). (C) Representative images of human SV- and
AAA-SMC, scale bar = 300 μm. (D) Quantification of apoptosis index in human SMC (n = 4). *P < 0.05, **P < 0.01, ***P < 0.001, ns = non-significant.
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breakdown of the ECM, with marked degradation of
elastin fibres [2]. In addition, collagenase activity is ele-
vated in AAA tissue [36,37]. Evidence from pathological
specimens suggests that loss of elastin is an early event
mediated by SMC [38] and is associated with production
of MMP-2 from SMC themselves [13,39]. Elevated ex-
pression levels of both MMP-2 mRNA and protein have
been reported in human and animal AAA tissue [6,7].
The observed deficiencies in PCA-SMC morphology and
proliferation after CCE treatment were also evident at
the level of MMP-2 secretion in which we observed,
contrary to previous reports, that both basal (constitu-
tive) and phorbol ester-stimulated secretion of MMP-2
from CCE-SMC was significantly lower than from VEH-
SMC. The unpaired nature of AAA-SMC and SV-SMC
precluded a direct comparison between them although
we noted that absolute levels of MMP-2 secretion from
AAA-SMC were consistently lower than from equivalentdensities of SV-SMC under identical conditions. Inter-
estingly, a study using tissue biopsies from the UK Small
Aneurysm Trial concluded that MMP-2 may only play
an “etiopathogenic” role in small (<5.5 cm) aneurysms
[40] and moreover, significant quantities were bound to
the ECM [7]. MMP-2 may actually provoke aneurysm
formation rather than propagate their growth, a concept
that could only be verified by conducting studies early in
the disease process. The availability of human early-
stage AAA tissue is however, scarce, primarily because
there is insufficient evidence to recommend surgical
intervention for small (<5.5. cm) AAA [1,41]. In the
present study we found no evidence of MMP-9 secretion
from either human or porcine SMC. Whilst MMP-9
levels were associated with AAA rupture in one study
[42], in another they were not [43].
To elucidate the function and fate of SMC in the
pathogenesis of AAA in man would necessitate access to
























































Figure 7 SMC senescence. Cells were cultured in FGM for 72 h before senescent cells were detected by β-galactosidase staining at pH 6.0.
(A) Representative images of PCA-SMC (blue precipitate is observed in senescent cells). Scale bar = 200 μm (n = 3). (B) Senescence score in
PCA-SMC (n = 3). (C) Representative images of human SV-and AAA-SMC, scale bar = 200 μm (n = 4). (D) Senescence score in human SMC
(n = 4). *P < 0.05, ***P < 0.001.
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sible, the need for appropriate laboratory models is evi-
dent. Whilst large animal models have chiefly been
employed to test endovascular stent devices, rodent
models have been useful in elucidating molecular mech-
anisms to identify new treatment options, all of which
have employed a range of techniques to induce the experi-
mental aneurysms (reviewed in [14]). Two consecutive
published studies support the concept that preservation of
vascular SMC content and functionality can limit early
aneurysm development. In the first, de-cellularised guinea
pig aortic scaffolds were implanted into rats and immedi-
ately infused with syngeneic rat SMC. After 8 weeks, ves-
sel expansion was diminished in the SMC-populated
vessels and the authors concluded that SMC conferred a
protective effect on the graft wall via a paracrine mechan-
ism [15]. Conversely, absence of SMC led to greater dilata-
tion, indicating that SMC perform important roles early in
aneurysm formation by protecting against inflammation
and proteolysis. A later, similar study by the same in-
vestigators introduced SMC to the graft 2 weeks afterimplantation in order to explore the effect of restoring
SMC function in a developing aneurysm. In that study,
SMC formed an intima over the top of accumulated
thrombus that appeared to stabilise the wall and pre-
vent further dilatation [16].
Of the animal models, porcine arterial vessels exhibit a
similar structure to man [14]. An in vivo porcine model
has also been previously generated by aortic perfusion of
a combination of collagenase and elastase to generate an
aneurysm [17]. Whilst such large models are valuable,
their size and cost implications are substantial, such that
time-course studies examining progression of AAA from
the early stages and beyond are routinely prohibitive.
Our study endorses the need for a robust ex vivo model
that is amenable to temporal study of SMC dysfunction.
After 12 days in the bioreactor, we observed that porcine
CCE-SMC appeared phenotypically and functionally
similar to SMC cultured from human “end-stage” tissue.
The design of our model is conducive to sequential
examination of SMC characteristics at earlier time










































Marker Basal     TPA Basal    TPA
SV AAA
Figure 8 MMP-2 secretion from SMC. Equal densities of SMC were cultured in basal media (0.4% FCS) in the presence or absence of 100 nM
TPA for 48 h. Conditioned media were analysed for MMP-2 secretion using gelatin zymography. (A) Mean densitometry data from SMC from
freshly isolated tissue, VEH and CCE-pre-treated vessels (all n = 3, ns = non significant, *P < 0.05, **P < 0.01, **P < 0.001). (B) Representative
zymogram. (C) Mean densitometry data from human SV and AAA-SMC (all n = 12, *P < 0.05, ***P < 0.001). (D) Representative zymogram.
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onstrated in a mouse model of AAA and associated with
changes in gene expression that are apparent well before
aneurysm formation is detected [6]. Given the imple-
mentation of national screening programmes for AAA
[44,45] it is likely that in the future, diagnosis can be
made much earlier in the natural history of the disease.
Importantly, such patients are those in whom medical
therapy may be pertinent by way of preserving SMC in-
tegrity and function through targeting them to a “repara-
tive” phenotype.
Conclusions
Loss of arterial wall structure and integrity by impaired
SMC function provides an explanation for the substan-
tial and progressive weakening of the aortic wall ob-
served in AAA. In order to understand early changes in
SMC behaviour, an ex vivo model is appropriate and
here we have shown that enzyme pre-treatment of por-
cine carotid arteries maintained for 12 days within a
bioreactor generates vessel wall disruption and SMC
aberrancies comparable to those of end stage human
tissue. Future studies with this engineered bioreactor
will allow control of the physical environment experienced
by the cultured tissues and thus it holds significant potential
for studying SMC dysfunction throughout early aneurysmdevelopment. Identifying key cellular and molecular
mechanisms that promote SMC loss and aneurysm ex-
pansion will inform new therapeutics to preserve SMC
content and integrity in the aortic wall.
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